MGC Pharmaceuticals Ltd (ASX: MXC)
MGC Pharmaceuticals Ltd (ASX: MXC) were requested to be placed on a trading halt pending the release of announcement regarding MGC Derma sale transaction with Canadian-based company CannaGlobal and the halt was requested to be until the earlier of the commencement of normal trading on 5 November 2018 or when the announcement is released to the market. In FY 2018, the revenue of the company increased by 146% from $120,242 in FY 2017 to $296,81 in FY 2018. The net loss of the company increased by 1.25 percent to $8.25 million. The net tangible asset per share decreased from 0.90 cents in FY 2017 to 0.50 cents in FY 2018. At the end of FY 2018, the company was having cash and cash equivalents of $9.86 million with no debt. During the September quarter, the company made a strong progress across multiple fronts by validating its seed-to-pharma strategy and signaling the start of commercialization for CannEpilTM in Australia, confirmed with the recent authorization granted by TGA to specialist prescribers who are now authorized to prescribe CannEpilTM to eligible patients in Australia. At the end of September quarter, the company was having cash of $8.5 million, leaving the Company well-funded to continue building out its seed-to-pharma operations, commence construction of its Maltese medical cannabis production and cultivation facility. MXC’s shares last traded at $0.051 with a market capitalization of circa $61.85 million.
Celsius Resources Limited (ASX: CLA)
Celsius Resources Limited (ASX: CLA)’s securities were suspended from trading on ASX on 1 November 2018, pending the release of an announcement. The company recently reported that the latest results from the ongoing resource expansion drilling program at Opuwo Cobalt Project continue to illustrate the consistent nature of the mineralization at Opuwo. At 30 September 2018, the company was having cash reserves of $10.7 million. At the end of the September quarter, the net cash used in operating activities was $1.75 million. In FY 2018, the net assets of the company increased to $22.3 million from $5.3 million in FY 2017. In the last six months, the share price of the company decreased by 47.50 percent as on 29 October 2018. CLA’s shares last traded at $0.105 with a market capitalization of $75.71 million.
Birimian Limited (ASX: BGS)
Birimian Limited (ASX: BGS) is a Perth based mineral exploration company. The company has continued to progress work on its Goulamina Lithium Project, following completion of an updated Pre-Feasibility Study (PFS) for the Project. The PFS was announced at the beginning of the September Quarter and confirmed the Project’s potential as a large, low-cost lithium producer. The Company declared the Project’s maiden Ore Reserve of 31.2Mt million tonnes, with significant potential to expand this and extend mine life through the identified exploration upside. The Project is forecasted to generate an average annual EBITDA of A$171M and a 49.5% internal rate of return which will deliver a short payback period of 2.6 years. In the first half of FY 2018, the company reported a net loss of $1.80 million. The basic and diluted loss per share of the company in the first half of FY 2018 was 1.0 cents. In the last six months, the share price of the company decreased by 65.74 percent as on 31 October 2018. BGS’s shares traded at $0.190 with a market capitalization of circa $43.21 million as on 1 November 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.